Gehen Sie mit der App Player FM offline!
FDA Approval! A New Model for BioPharma... Dr. Sam Blackman, Founder & Head of Research and Development, One Day Biopharmaceuticals
Manage episode 421961118 series 3360496
This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. Driven by the urgent need for pediatric oncology treatments, Day One's innovative approach led to the development of tovorafenib, targeting BRAF-altered pediatric low-grade gliomas. Through the FireFLY trial, they demonstrated significant efficacy, with 52% of patients experiencing tumor shrinkage and 82% showing benefits. Dr. Blackman emphasizes the importance of hope in drug development and discusses Day One's future plans to expand treatment options for childhood cancer.
88 Episoden
Manage episode 421961118 series 3360496
This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. Driven by the urgent need for pediatric oncology treatments, Day One's innovative approach led to the development of tovorafenib, targeting BRAF-altered pediatric low-grade gliomas. Through the FireFLY trial, they demonstrated significant efficacy, with 52% of patients experiencing tumor shrinkage and 82% showing benefits. Dr. Blackman emphasizes the importance of hope in drug development and discusses Day One's future plans to expand treatment options for childhood cancer.
88 Episoden
Alle Folgen
×Willkommen auf Player FM!
Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.